ArticlePharmacoEconomics2009

Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Annemieke De Ridder et al.PubMed ↗Publisher ↗

No numbers read from the abstract.